Pretransplantation characteristics
| . | KIR ligand match . | KIR ligand mismatch . | All . |
|---|---|---|---|
| Diagnosis, no. (% of total) | |||
| All | 38 (100) | 67 (100) | 105 (100) |
| AML | 28 (74) | 53 (79) | 81 (77) |
| MDS | 10 (26) | 14 (21) | 24 (23) |
| Recipient age, y (range) | |||
| All | 46 (2.5-65) | 40 (1-64) | 42 (1-65) |
| AML | 46 (8-65) | 40 (1-64) | 41 (1-65) |
| MDS | 54 (2.5-63) | 34 (1-67) | 42 (1-67) |
| Donor age, y (range) | 47 (0.5-71) | 36 (3-66) | 43 (0.5-71) |
| AML remission, no. (%) | |||
| First | 17 (45) | 41 (61) | 58 (55) |
| Second | 6 (16) | 6 (9) | 12 (11) |
| Third | 1 (3) | 1 (1) | |
| Refractory | 4 (11) | 3 (4) | 7 (7) |
| Relapse | 1 (3) | 4 (6) | 5 (5) |
| Conditioning, no. (%) | |||
| TBI based | 8 (21) | 14 (21) | 22 (21) |
| Busulfan + cyclophosphamide | 15 (39) | 41 (61) | 56 (53) |
| Busulfan + fludarabine | 15 (39) | 12 (18) | 27 (26) |
| RIC, no. (%) | 16 (42) | 13 (19) | 29 (28) |
| ATG, no. (%) | |||
| Rabbit-ATG | 8 (21) | 8 (12) | 16 (15) |
| Campath | 4 (11) | 3 (4) | 7 (7) |
| Cell no./kg, median (range) | |||
| CD34 (×106) | 7.6 (0.5-18) | 6.8 (1.5-22) | 7.5 (0.5-22) |
| CD3 (×106) | 283 (63-723) | 244 (14-919) | 254 (14-919) |
| TNC (×108) | 11 (1.6-24) | 8,5 (0.7-47) | 10 (0.7-47) |
| GVHD prophylaxis, no. (%) | |||
| MTX + cyclosporine | 37 (97) | 62 (93) | 99 (94) |
| Other | 1 (3) | 7 (10) | 8 (8) |
| Stem cell source, no. (%) | |||
| BM | 10 (26) | 25 (37) | 35 (33) |
| PBSC | 28 (74) | 42 (63) | 70 (67) |
| DLI, no. (%) | 13 (34) | 15 (22) | 28 (27) |
| Recipient/donor CMV status, no. (%) | |||
| Positive/positive | 23 (61) | 29 (43) | 52 (50) |
| Positive/negative | 8 (21) | 22 (33) | 30 (29) |
| Negative/negative | 3 (8) | 8 (12) | 11 (10) |
| Negative/positive | 4 (11) | 6 (9) | 10 (10) |
| Recipient/donor sex, no. (%) | |||
| M/M | 15 (39) | 22 (33) | 37 (35) |
| M/F | 6 (16) | 16 (24) | 22 (21) |
| F/M | 10 (26) | 16 (24) | 26 (25) |
| F/F | 7 (18) | 13 (19) | 20 (19) |
| Follow-up, y (range) | 5.4 (0.3-16) | 4.7 (0.2-20) | 5.7(0.2-20) |
| . | KIR ligand match . | KIR ligand mismatch . | All . |
|---|---|---|---|
| Diagnosis, no. (% of total) | |||
| All | 38 (100) | 67 (100) | 105 (100) |
| AML | 28 (74) | 53 (79) | 81 (77) |
| MDS | 10 (26) | 14 (21) | 24 (23) |
| Recipient age, y (range) | |||
| All | 46 (2.5-65) | 40 (1-64) | 42 (1-65) |
| AML | 46 (8-65) | 40 (1-64) | 41 (1-65) |
| MDS | 54 (2.5-63) | 34 (1-67) | 42 (1-67) |
| Donor age, y (range) | 47 (0.5-71) | 36 (3-66) | 43 (0.5-71) |
| AML remission, no. (%) | |||
| First | 17 (45) | 41 (61) | 58 (55) |
| Second | 6 (16) | 6 (9) | 12 (11) |
| Third | 1 (3) | 1 (1) | |
| Refractory | 4 (11) | 3 (4) | 7 (7) |
| Relapse | 1 (3) | 4 (6) | 5 (5) |
| Conditioning, no. (%) | |||
| TBI based | 8 (21) | 14 (21) | 22 (21) |
| Busulfan + cyclophosphamide | 15 (39) | 41 (61) | 56 (53) |
| Busulfan + fludarabine | 15 (39) | 12 (18) | 27 (26) |
| RIC, no. (%) | 16 (42) | 13 (19) | 29 (28) |
| ATG, no. (%) | |||
| Rabbit-ATG | 8 (21) | 8 (12) | 16 (15) |
| Campath | 4 (11) | 3 (4) | 7 (7) |
| Cell no./kg, median (range) | |||
| CD34 (×106) | 7.6 (0.5-18) | 6.8 (1.5-22) | 7.5 (0.5-22) |
| CD3 (×106) | 283 (63-723) | 244 (14-919) | 254 (14-919) |
| TNC (×108) | 11 (1.6-24) | 8,5 (0.7-47) | 10 (0.7-47) |
| GVHD prophylaxis, no. (%) | |||
| MTX + cyclosporine | 37 (97) | 62 (93) | 99 (94) |
| Other | 1 (3) | 7 (10) | 8 (8) |
| Stem cell source, no. (%) | |||
| BM | 10 (26) | 25 (37) | 35 (33) |
| PBSC | 28 (74) | 42 (63) | 70 (67) |
| DLI, no. (%) | 13 (34) | 15 (22) | 28 (27) |
| Recipient/donor CMV status, no. (%) | |||
| Positive/positive | 23 (61) | 29 (43) | 52 (50) |
| Positive/negative | 8 (21) | 22 (33) | 30 (29) |
| Negative/negative | 3 (8) | 8 (12) | 11 (10) |
| Negative/positive | 4 (11) | 6 (9) | 10 (10) |
| Recipient/donor sex, no. (%) | |||
| M/M | 15 (39) | 22 (33) | 37 (35) |
| M/F | 6 (16) | 16 (24) | 22 (21) |
| F/M | 10 (26) | 16 (24) | 26 (25) |
| F/F | 7 (18) | 13 (19) | 20 (19) |
| Follow-up, y (range) | 5.4 (0.3-16) | 4.7 (0.2-20) | 5.7(0.2-20) |
TBI indicates total body irradiation; RIC, reduced-intensity conditioning; TNC, total nuclear cell count; MTX, methotrexate; BM, bone marrow; PBSC, peripheral blood stem cell; DLI, donor lymphocyte infusion; M, male; and F, female.